Vizuro LLC, an innovator in multimodal causal AI technology, and the Development Center for Biotechnology (DCB) announced the signing of a Memorandum of Understanding (MoU) to collaboratively drive innovation and growth in the biotechnology and pharmaceutical industries.

The collaboration aims to establish a next-generation AI computational platform, advancing breakthroughs in drug discovery and accelerating the implementation of precision medicine. The partnership paves the way for ground-breaking advancements in the global biotech industry.

The MoU outlines collaboration in nine major areas, including small-molecule drugs, antibody-drug conjugates (ADC), bispecific antibodies, antisense oligonucleotides (ASO), small interfering RNA (siRNA), antibody-oligonucleotide conjugates (AOC), induced pluripotent stem cells (iPSC), CAR-NK cell therapy and cancer vaccines.

The partnership will also collaborate on securing resources from the Ministry of Economic Affairs, China, and NVIDIA's ‘Taipei-1’ A+ program to boost the platform's AI computational capabilities. This enhanced capacity will support multimodal drug discovery and accelerate the clinical application of innovative therapies. By combining their unique expertise, Vizuro and DCB aim to create next-generation biotech products and platforms, driving progress in both research and commercial ventures.

Commenting on the development, Yu-Feng Wei, Co-Founder and CEO of Vizuro LLC, stated, “The causal generative AI platform developed by Vizuro enables significant advancements in drug discovery. It expands potential biological pathways, enhances target discovery, repositions drugs, and generates novel drug designs while identifying biomarkers suited for specific clinical populations.”

He further added, “By combining DCB's extensive expertise in drug development and start-up incubation with Vizuro's capabilities in causal and generative AI technology, this collaboration represents a powerful synergy. The integration of generative AI technology makes drug discovery processes more precise and efficient. This partnership with DCB opens new opportunities in drug discovery, injecting fresh momentum into the growth of Taiwan's biotech and pharmaceutical industries.”

Dr. Hsing-Jer Tsou, DCB Chairman, emphasized, “Generative AI technology significantly enhances the efficiency of target exploration and drug design. By collaborating with Vizuro, a leader in generative AI, DCB aims to accelerate cancer drug development. This partnership is expected to yield niche, first-in-class, or best-in-class drugs while fostering an ecosystem for academic, industrial, and research collaborations in early-stage drug discovery. The ultimate goal is to deliver innovative medicines that benefit patients worldwide.”

Dr. Chien-Yueh Huang, DCB Deputy Executive Director, highlighted, “DCB's robust preclinical drug development capabilities, with extensive experience in small-molecule drugs, biologics, and nucleic acid therapeutics. Vizuro, with offices in Boston and Taipei, specialises in generative AI and offers actionable AI solutions across various industries. Its expertise lies in combining deep learning and causal inference to identify biological targets and simulate drug designs from multimodal data. Together, DCB and Vizuro plan to build an AI computational platform to advance drug discovery and repositioning, efficiently finding new therapeutic uses for existing drugs. This will accelerate the development of cost-effective, precise, and rapid new medicines.”

This collaboration marks a major leap forward in generative AI in the biotechnology and pharmaceutical sectors. It establishes a new standard for integrating AI technologies and propelling Taiwan's biotech industry into the global market.